Purpose The purpose of this study was to assess the cost saved and the amount of drug wasted when compounding anticancer drugs in the centralized unit for chemotherapy preparation. A secondary objective was to estimate the centralization impact of activities related to the preparation of chemotherapies. Methods This was a two-month, single-centre, prospective study conducted at the National Oncology Institute in Rabat. The cost saved and the amount of drug wasted were calculated using a standardized data collection sheet (the prescribed dose, the amount of drug deployed, the amount remaining after compounding, the amount of drug saved and the drug wastage). The centralization impact was calculated using the amount of drug wasted in the centralized unit for chemotherapy preparation and a theoretical amount of drug wasted without centralization of preparation. Results During the study period, the total amount of drug saved was 249,959.5 mg (7.2% of drug used), which represented 96,657 USD. The amount of drug wasted was 89,290.5 mg or 42275.5 USD. The drug waste per dilution and per drug was 6.4 mg [1.6-16.1]. While the potential savings over one year (580,000 USD) reached 13.9% of the cytostatic drugs budget for 2018, the potential drug waste cost reached 6.1%. The centralization impact is estimated at an average of 79.5% ± 13.7% waste reduction. Conclusion The outcome of our study showed that the grouping of prescriptions in centralized unit for chemotherapy preparation could result in significant savings on the amount of drugs deployed. The centralization of cytostatic preparations is of economic interest.

No abstract

No abstract

BackgroundCisplatin, carboplatin and oxaliplatin are three major platinum salts used for intravenous chemotherapy. However, their efficacy is accompanied by different toxicities.PurposeThe aim of our study is to identify adverse drug reactions of platimum salts.Material and methodsAn observational prospective analysis was conducted between March 2014 and September 2015 in the oncology sector of a central hospital. Data were collected and analysed using Excel 2013. We collaborated with the National Centre of Pharmacovigilance for fresh imputability analysis.ResultsThe study included 70 patients, the average age was 52 years and the sex ratio (F/M) was 0.41. The most frequent cancers were colorectal cancer (46% of patients) and cervical cancer (18%). Oxaliplatin was the most commonly reported molecule (45%).During 18 months of study, we collected 222 adverse drug reactions with sensory and neurosensory toxicities (26% and 21%, respectively).Peripheral neuropathy, digestive intolerance and haematological toxicities were attributed to platinum salts with an I2B4 score.ConclusionPlatinum salts cause several complications, especially neurosensory toxicities. The pharmacist has an important role in monitoring post-chemotherapy, which avoids and prevents many adverse events.Reference and/or Acknowledgements1. Jean-Pasto MJ. Hypersensitivity to platinum salts: pharmacovigilance, pulmonology. Revue des Maladies RespiratoiresNovember 2006;23(5):487–488.No conflict of interest